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Objective: Although carotid endarterectomy (CEA) is performed to prevent stroke, long-term survival is essential to
ensure beneﬁt, especially in asymptomatic patients. We examined factors associated with 5-year survival following CEA in
patients with asymptomatic internal carotid artery (ICA) stenosis.
Methods: Prospectively collected data from 4114 isolated CEAs performed for asymptomatic stenosis across 24 centers in
the Vascular Study Group of New England between 2003 and 2011 were used for this analysis. Late survival was
determined with the Social Security Death Index. Cox proportional hazard models were used to identify risk factors for
mortality within the ﬁrst 5 years after CEA and to calculate a risk score for predicting 5-year survival.
Results:Overall 3- and 5-year survival after CEA in asymptomatic patients were 90% (95% CI 89%-91%) and 82% (95% CI
81%-84%), respectively. By multivariate analysis, increasing age, diabetes, smoking history, congestive heart failure,
chronic obstructive pulmonary disease, poor renal function (estimated glomerular ﬁltration rate <60 or dialysis depen-
dence), absence of statin use, and worse contralateral ICA stenosis were all associated with worse survival. Patients
classiﬁed as low (27%), medium (68%), and high risk (5%) based on number of risk factors had 5-year survival rates of
96%, 80%, and 51%, respectively (P < .001).
Conclusions: More than four out of ﬁve asymptomatic patients selected for CEA in the Vascular Study Group of New
England achieved 5-year survival, demonstrating that, overall, surgeons in our region selected appropriate patients for
carotid revascularization. However, there were patients selected for surgery with high risk proﬁles, and our models
suggest that the highest risk patients (such as those with multiple major risk factors including age$80, insulin-dependent
diabetes, dialysis dependence, and severe contralateral ICA stenosis) are unlikely to survive long enough to realize
a beneﬁt of prophylactic CEA for asymptomatic stenosis. Predicting survival is important for decision making in these
patients. (J Vasc Surg 2013;58:112-9.)Carotid endarterectomy (CEA) is commonly per-
formed for primary and secondary stroke prevention, with
nearly 120,000 CEAs performed annually in the United
States.1 Evidence supporting CEA for the treatment of
cerebrovascular disease is well-established and demon-
strates a substantial reduction in the risk of stroke for
patients with symptomatic disease.2 However, in the facethe Dartmouth Hitchcock Medical Center, Lebanona; Fletcher Allen
ealth Care, Burlingtonb; the UMass Memorial Health Care, Amherstc;
d the Maine Medical Center, Portland.d
oodney was supported by a K08 Award (K08 HL05676) from the
HLBI and a Society for Vascular Surgery Foundation Lifeline Award.
or conﬂict of interest: none.
ented as a plenary presentation at the 2012 Vascular Annual Meeting
the Society for Vascular Surgery, National Harbor, Md, June 9,
12.
int requests: Jessica B. Wallaert, MD, VAOutcomes Group, Dartmouth-
itchcock Medical Center, One Medical Center Drive, Lebanon
H 03765 (e-mail: jessica.wallaert@hitchcock.org).
editors and reviewers of this article have no relevant ﬁnancial relationships
disclose per the JVS policy that requires reviewers to decline review of any
anuscript for which they may have a conﬂict of interest.
-5214/$36.00
yright  2013 by the Society for Vascular Surgery. Published by
sevier Inc. All rights reserved.
://dx.doi.org/10.1016/j.jvs.2012.12.056of improving medical therapy, many have begun to call
into question the appropriateness of CEA for asymptomatic
patients,3,4 where the net beneﬁt from preventative surgery
is signiﬁcantly less than that for patients with symptomatic
stenosis.5,6
In terms of establishing “appropriateness” for asymptom-
atic CEA, several professional societies, including the Society
for Vascular Surgery7 and the American Heart Association,8
offer guidelines stating that asymptomatic patients with at
least a 60% carotid artery stenosis should be considered for
CEA only if the patient has a predicted risk of perioperative
stroke/death that is #3% and a minimum life expectancy of
3-5 years. Although many models exist to predict patients’
risk of perioperative stroke/death,9,10 similar data donot exist
tohelp surgeons select patientswhose life expectancy is at least
3-5 years from the timeof surgery. In fact, our priorwork indi-
cates that as many as 20% of asymptomatic CEAs are per-
formed in patients with life limiting conditions, one-half of
whom are unlikely to survive 5 years from the time of
CEA.11 Therefore, the purpose of this study was to describe
long-term survival in asymptomatic patients undergoing
CEA using data from the Vascular Study Group of New
England (VSGNE). We used these data to develop a model
for predicting a patient’s risk of death within 5 years, to aid
surgeons in their clinical decision making.
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Subjects and databases. For this report, we analyzed
data collected as part of the VSGNE, a regional cooperative
quality improvement initiative developed in 2002. Further
details on the registry have been published previously12 and
are available at www.vsgne.org.
Data were examined from 8021 patients undergoing
primary, unilateral CEA performed by 114 participating
surgeons, across 24 study hospitals between January 1,
2003 and January 1, 2011. Of these, we excluded 187
that were combined with coronary artery bypass graft,
leaving 7834 isolated, primary CEAs for our analysis.
Trained nurses, physicians, or clinical data abstractors
entered data prospectively on over 100 clinical and demo-
graphic variables. Mortality was determined by matching
patients with the Social Security Death Index.
Establishing a cohort of asymptomatic patients.
Because the indications for revascularization of symptom-
atic carotid stenosis vary dramatically from those for asymp-
tomatic disease, all patients with any prior symptoms were
excluded from our analysis. Symptomatic status was
assigned to 3656 patients with a documented history of
one or more of the following: ipsilateral or contralateral
ocular or cortical cerebrovascular accident or transient
ischemic attack (TIA); vertebrobasilar cerebrovascular acci-
dent or TIA; or “non-speciﬁc” symptoms. An additional
64 patients underwent CEAs classiﬁed as urgent or emer-
gent and were assumed to be symptomatic. The remaining
4114 patients were designated as asymptomatic (elective
surgery, no history of any cerebrovascular symptoms) and
were included in our cohort for analysis. All stenosis criteria
were determined by duplex ultrasonography.
Predicting 5-year mortality following CEA. Survival
analysis was performed in two ways. First, Kaplan-Meier
survival analysis with log-rank test (for categorical vari-
ables) and Cox proportional hazard regression (for contin-
uous variables) were used to examine univariate associations
between mortality and a variety of patient, operative, and
hospital characteristics. Second, all variables that were
associated with mortality with P < .2 were entered into
a multivariate model and backwards stepwise Cox propor-
tional hazard regression with nested likelihood ratios was
performed to generate a ﬁnal model for predicting mortality
at 5 years.
Assignment of low, medium, or high risk classiﬁ-
cation to each patient in the cohort. Next, we created
three strata of risk for mortality: low, medium, and high.
To establish these risk strata, each covariate in our predic-
tion model was classiﬁed as either a major or minor risk
factor for mortality based on the relative contribution of
the variable to the ﬁnal regression equation. Relative
contribution was determined by examining the b-coefﬁ-
cient for each covariate, indexed to the lowest b-coefﬁcient
in our model (.22). Weighted point-values ranged from 1
(for estimated glomerular ﬁltration rate <60 and contra-
lateral internal carotid artery [ICA] stenosis 50%-80%) to 6
(for age $80). Those variables with a point-value less than3 were designated as minor risk factors for mortality, and
those with weighted points greater than 3 were deemed
major risk factors for mortality. In total, we identiﬁed four
major risk factors including age $80, insulin-dependent
diabetes, dialysis dependence, and contralateral ICA
stenosis 80%-99%. The remaining covariates in the model
were deemed minor risk factors and included age 70-80
years, noninsulin-dependent diabetes, smoking history,
congestive heart failure (CHF), chronic obstructive
pulmonary disease (COPD), estimated glomerular ﬁltra-
tion rate <60, absence of statin, contralateral ICA stenosis
50%-80%, or contralateral ICA occlusion. Next, categories
of risk were deﬁned based on discrete cut points in the
number of major and minor risk factors present. Each
patient in the cohort was designated as high, medium, or
low risk based on these cut points.
Calculating risk scores to predict 5-year survival.
Because not every patient who presents for consideration of
surgery will ﬁt perfectly into one of our three classiﬁcations
of risk, we also generated a more precise risk scoring
system. Risk scores were calculated by summing the
indexed beta coefﬁcients for each covariate in our model
for each individual. Cut points for deﬁning patients as
low, medium, or high risk were selected based on the distri-
bution of risk scores. Predicted 5-year survival was then
calculated for a range of risk scores. All analyses were
performed using Microsoft Excel 2010 and StataIC 12
(College Station, Tex).
RESULTS
Patient characteristics and univariate analysis of
5-year survival. Overall, 4114 patients underwent CEA
for asymptomatic stenosis. Fifty-eight percent of patients
were male, and mean age was 70 years. The most prevalent
comorbidities included hypertension (89%), coronary
artery disease (CAD, 33%) and smoking history (80%).
Patient characteristics associated with a signiﬁcant reduc-
tion in 5-year survival on univariate analysis included age
$80 years, insulin-dependent diabetes, smoking history,
CAD, CHF, COPD, dialysis dependence, lack of statin use,
and contralateral ICA stenosis $50%. (Rates and signiﬁ-
cance levels are shown in Table I).
Main outcome measure: 5-year survival. Overall,
5-year survival for all patients in the cohort was 82%. By
multivariate analysis, increasing age, diabetes, smoking
history, CHF, COPD, poor renal function, degree of
contralateral ICA stenosis, and lack of statin therapy were
all associated with worse 5-year survival (hazard ratios are
shown in Table II). Of note, perioperative mortality in our
region was very low for patients undergoing CEA for
asymptomatic stenosis, with only 0.4% of patients experi-
encing death within 30 days. Similarly, the incidence of
perioperative stroke was also very low at 0.6%.
Identiﬁcation of low, medium, and high risk patients
by number of risk factors. As outlined in the Methods
section, we divided our cohort into three risk strata: high
(three major or two major plus $two minor risk factors),
Table I. Characteristics of patients undergoing CEA for asymptomatic stenosis and associated univariate relationship with
5-year survival
Percent of total cohort
Percent of the 4114 patients who achieved 5-year
survival following CEA
P valueaIf variable NOT present If variable IS present
Age, years
<70 47 84 92 <.001
70-79 39 89 85 .001
$80 14 88 79 <.001
Male sex 58 88 87 .36
Diabetes
Nondiabetic 68 85 89 <.001
Diet or oral medication controlled 23 88 86 .07
Insulin dependent 9 88 83 <.001
Past or current smoking history
Never smoker 20 87 91 <.001
Past (>1 year prior) 52 89 87 .006
Current smoker 28 88 87 .96
Hypertension 89 87 88 .54
Coronary artery disease 33 90 84 <.001
CHF 8 89 78 <.001
COPD 21 90 81 <.001
Renal function
eGFRb $ 60 60 83 91 <.001
eGFRb < 60 40 91 84 <.001
Dialysis dependent <1 88 50 <.001
Aspirin 88 84 88 .44
Clopidogrel 12 87 90 .80
Statin 80 83 89 .08
Degree of ipsilateral ICA stenosis
<50% <1 88 95 .36
50%-59% 1 88 90 .76
60%-69% 2 88 86 .96
70%-79% 22 88 89 .78
$80%-99% 74 89 87 .94
Occluded <1 88 95 .33
Degree of contralateral ICA stenosis
<50% 57 86 89 <.001
50%-79% 33 88 87 .07
$80%-99% 4 88 82 .023
Occluded 6 88 82 .046
Shunt
None 57 89 87 .60
Routine 39 87 89 .20
Selective 4 88 83 .07
CEA, Carotid endarterectomy; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular ﬁltration rate; ICA,
internal carotid artery.
aP value reported for log-rank test.
beGFR in mL/min.
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(<two minor risk factors). In total, 27% of patients in our
region were low risk, deﬁned as having one or two minor
risk factors. An additional 65% were medium risk, deﬁned
as having one major or up to three minor risk factors, and
the remaining 5% were high risk, deﬁned as having three
major or two major plus two minor risk factors. Five-year
survival for low, medium, and high risk patients was 94%,
80%, and 51%, respectively (Fig 1).
Predicted 5-year survival based on risk score. The
highest possible risk score was 26 representing a patient
with all risk factors, and the lowest was 0, representing
patients with no risk factors. Predicted 5-year survivalranged from <0.1% for the highest risk score of 26, to 96%
for a risk score of 0 (Fig 2). In VSGNE, all patients had risk
scores less than 20 (ie, no asymptomatic patient with a risk
score higher than 20 was selected for surgery). Fig 3 shows
a comparison of predicted 5-year survival based on risk score
and actual 5-year survival for patients in our cohort based on
ranges of risk score. This ﬁgure demonstrates that our
prediction model ﬁts well across a wide range of risk scores.
DISCUSSION
The Society of Vascular Surgery guidelines state that
asymptomatic patients selected for CEA should have
a minimum life expectancy of 3 years and a risk of
Table II. Multivariate model for reduced 5-year survival
following CEA for asymptomatic stenosis




<70 Referent - -
70-79 1.8 1.4-2.2 <.001
$80 3.94 3.0-5.1 <.001
Diabetes
Nondiabetic Referent - -
Diet or oral medication
controlled
1.34 1.1-1.7 .008
Insulin dependent 1.98 1.5-2.7 <.001
Past or current smoking history 1.68 1.3-2.2 <.001
CHF 1.78 1.4-2.3 <.001
COPD 1.66 1.4-2.0 <.001
Renal function
eGFRa $ 60 Referent - -
eGFRa < 60 1.30 1.1-1.6 .007
Dialysis dependent 3.41 1.6-7.2 .001
Not on statin 1.27 1.1-1.6 .021
Degree of contralateral ICA
stenosis
<50% Referent - -
50%-80% 1.25 1.1-1.5 .032
>80%-99% 1.95 1.3-2.9 .001
Occluded 1.69 1.2-2.4 .002
CEA, Carotid endarterectomy; CHF, congestive heart failure; CI, conﬁ-
dence interval; COPD, chronic obstructive pulmonary disease; eGFR, esti-
mated glomerular ﬁltration rate; HR, hazard ratio; ICA, internal carotid
artery.
aeGFR in mL/min.
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4000 patients undergoing CEA for asymptomatic carotid
stenosis, we utilized data from our regional registry, linked
with the Social Security Death Index, to determine that 90%
of patients selected for surgery in theVSGNE survived at least
3 years following their procedure and more than four out of
ﬁve patients achieved 5-year survival. Our region also has
low rates of perioperative stroke (0.6%) and death (0.4%).
The clinical detail available in our registry allowed us to iden-
tify several major risk factors (such as age $80 and dialysis
dependence) and minor risk factors (such as CHF and
COPD) associated with death prior to 5 years after surgery.
Several prior population-based studies have described preva-
lence and risk factors for cerebrovascular disease.13,14 Similar
studies have examined the impact of cerebrovascular disease
on survival.15-18 As with our study, this literature highlights
the important role risk factors such as age, smoking, and dia-
betes play in determining outcomes in patients with cerebro-
vascular disease. However, our study adds to the current
literature in that we examine long-term survival among
patients whose carotid disease was deemed advanced enough
to warrant revascularization. Further, our study offers a tool
surgeons can use to predict survival for individual patients
being offered CEA based on actual survival data from similar
patients.
Appropriateness of CEA for asymptomatic stenosis.
In the 1990s, several large prospective trials including the
Asymptomatic Carotid Atherosclerosis Study (ACAS),5 theAsymptomatic Carotid Surgery Trial,6 and the Veterans
Cooperative Affairs Trial19 established the small but
measurable beneﬁt of CEA over medical therapy alone for
the prevention of stroke in patients with asymptomatic ICA
stenosis. Many professional societies used these trials to
deﬁne appropriateness criteria for surgery in asymptomatic
patients.8,20,21 However, despite evidence from landmark
trials, many have called into question the appropriateness of
CEA for asymptomatic patients in real-world clinical prac-
tice. For example, in 1999 Gould et al performed a study
comparing the efﬁcacy (determined from results of ACAS)
and effectiveness (based on real-world clinical data) of CEA
in asymptomatic patients with severe ICA stenosis. This
study found that trial data suggests the number needed to
treat to prevent one major stroke or death in asymp-
tomatic patients is 38. However, estimated complication
rates from real-world practice, where a higher proportion
of patients undergoing CEA are older and have more
comorbid conditions than those enrolled in ACAS, is
nearly twice as high, with 63 patients needed to treat to
prevent one major stroke or death 63.22 Wennberg
et al23 also questioned how well the results from
randomized trials had translated into clinical practice, by
demonstrating that patients undergoing CEA outside of
randomized clinical trials had signiﬁcantly higher rates of
perioperative mortality than their presumed healthier
counterparts enrolled in ACAS and North American
Symptomatic Carotid Endarterectomy Trial (NASCET).
These questions regarding CEA, initially posed in the
late 1990s, were followed by substantial changes in medical
therapy, such as more widespread use of antiplatelet agents
and statins.24 As a result, more have begun to question
whether CEA continues to offer beneﬁt over medical
management in asymptomatic patients. For example,
a recent meta-analysis, performed by Abbott in 2009, exam-
ined trends over time in the incidence of stroke in asymp-
tomatic patients managed with medical therapy alone who
were enrolled in clinical trials. This study demonstrated
a 7% decrease the rate of ipsilateral stroke/TIA between
1985 and 2005, with a corresponding increase in the use
of aspirin at baseline.4 Unfortunately, data pertaining to
baseline use of statins over this time period were largely
unreported, a “testament to the unavailability of many
now commonly used drugs and the growing appreciation
of the signiﬁcant impact they have on vascular risk,” noted
by Abbott.4 A similar study reporting the effect of medical
therapy on stroke risk in patients with asymptomatic ICA
stenosis was performed by Spence et al. This study compared
rates of spontaneous microemboli detection by transcranial
Doppler, as well as incidence of stroke/death/myocardial
infarction between patients seen before 2003 and those
seen after 2003. The ﬁndings demonstrated a signiﬁcant
reduction in microemboli (12.6% vs 3.7%), a signiﬁcant
reduction in cardiovascular events (17.6% vs 5.6%), and
a corresponding reduction in total plasma cholesterol (179
mg/dL pre-2003 vs 166 mg/dL post-2003).25
Although controversy over what constitutes appro-
priate indication for CEA in asymptomatic patients persists,
Fig 2. Predicted 5-year survival following carotid endarterectomy (CEA) for asymptomatic stenosis based on calcu-
lated risk score.
Fig 1. Five-year survival following carotid endarterectomy (CEA) for asymptomatic stenosis in low, medium, and high
risk patients. CHF, Congestive heart failure; COPD, chronic obstructive pulmonary disease; eGFR, estimated
glomerular ﬁltration rate; ICA, internal carotid artery.
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other causes, in whom CEA is not the preferred manage-
ment strategy. For example, our recent work examined
the incidence and outcomes of CEA in asymptomatic
patients with life-limiting conditions, such as severe
COPD, symptomatic CHF, and metastatic cancer. We
found that 20% of asymptomatic CEAs are performed inpatients with poor predicted long-term survival. Further,
these patients fare worse in the postoperative period, expe-
riencing signiﬁcantly higher rates of postoperative stroke
and death than their unafﬂicted counterparts.11 Similarly,
Cronenwett et al demonstrated that CEA is not cost-
effective when performed in patients over the age of
7026; Ascher et al highlighted worse outcomes among
Fig 3. Comparison of predicted 5-year survival (line) to actual 5-year survival (columns) based on calculated risk score
for asymptomatic patients undergoing carotid endarterectomy (CEA).
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undergoing CEA27; and Chaturvedi et al highlighted
increased risk following CEA among African Americans.28
The current study adds to this body of literature, indicating
that there are high risk patients, speciﬁcally those with
multiple major risk factors such as age $80, insulin-
dependent diabetes, dialysis dependence, and severe
contralateral stenosis, who are unlikely to beneﬁt from
prophylactic CEA based on long-term survival. Further,
our study offers several user-friendly prediction rules to
assist surgeons in identifying these high risk patients.
Limitations. Our study has several limitations. First,
our long-term outcome measure is survival, rather than
stroke-free survival. Cause of death was not available for
patients in our registry nor could we determine if they
remained stroke-free between the date of their procedure
and the date of their long-term follow-up. Second, our
procedure-based registry only contains those patients who
underwent a procedure, and thus, we have no medical
treatment arm for comparison. Third, several of the risk
factors we deﬁned as major predictors of mortality, such as
dialysis dependence and contralateral ICA stenosis 80%-99%,
were only present in a small subset of our cohort. However,
because the dataset examined was so large, the absolute
numbers provided were substantial enough to generate
sound prediction rules. Finally, the data used to derive our
prediction models are from a regional registry and therefore
may not be generalizable to regions where quality improve-
ment programs are not widespread. Our future work will aim
to externally validate these prediction rules using a national
database, whichwill serve to test the statistical strength of our
predictive model on a larger, nonregionalized population.
Summary. More than four out of ﬁve asymptomatic
patients selected for CEA in New England achieved 5-year survival with 30-day stroke/death rates less than 1%.
However, a small proportion of patients selected for
surgery had high risk proﬁles, such as those with multiple
major risk factors including age $80, insulin-dependent
diabetes, dialysis dependence, and severe contralateral
ICA stenosis. Our study demonstrates that these patients
are unlikely to survive long enough to realize a beneﬁt of
CEA for asymptomatic stenosis. In the current healthcare
environment, where vascular surgeons strive to improve the
value and appropriateness of carotid revascularization,
especially in asymptomatic patients,29 predicting survival is
especially important for decision making in patients with
asymptomatic carotid atherosclerosis. Our prediction
models appear to help with these decisions, as they
discriminate well between patients who will and will not
survive long-term following CEA, and will be made avail-
able online for public use to help surgeons appropriately
select patients for carotid revascularization.
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the data set which is incomplete is on those patients who did
not get operated on who are at high risk. Do you have any idea
of exactly what the stroke rate was in that population?
Dr Jessica B. Wallaert. We don’t. The VSGNE registry only
has data for patients who underwent surgery. We agree that one of
the biggest limitations to our study is this lack of a control group.
It could be that patients who are at high risk for mortality are also
at highest risk for experiencing stroke if they don’t undergo endar-
terectomy. Unfortunately, we don’t have the data needed to
compare rates of stroke-free survival in medically managed patients
to long-term survival for patients in our registry.
Dr Richard Cambria (Boston, Mass). You wrote a paper in
Stroke on the same topic using a different databasedI believe it
was Medicaredso could you give us an insight into the compara-
tive data between the two, if they’re similar or not?My second question is how did you do the late survival data in
this study? Our database doesn’t really capture that survival data,
so did you just use Social Security Death Index or what?
And, my last question is really a comment that the limitations
of the database are such that there may be mitigating factors that
cause a surgeon to make a decision in an asymptomatic patient,
such as demonstrated progression with sequential follow-up, that
aren’t captured in the database that might affect clinical decision
making.
Dr Wallaert. Our recent article in Stroke described the inci-
dence and outcomes of carotid endarterectomy in asymptomatic
patients deﬁned as having life-limiting conditions using the Amer-
ican College of Surgeons National Surgical Quality Improvement
Program Registry (ACS-NSQIP). The results were strikingly
similar to those presented today, using our regional registry. In
ACS-NSQIP, we found that 20% of patients are unlikely to survive
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dicted long-term mortality. The current study uses actual mortality
and found that 18% of patients die within 5 years following endar-
terectomy. In both studies, incidence of postoperative stroke,
death, and myocardial infarction were also higher in patients
deﬁned as high risk. Overall, the results from these two separate
databases gave quite similar results.
Regarding your second question about late survival, all of the
data from VSGNE were linked to Social Security Death Index to
determine mortality for this study.
Dr Jacob Schneiderman (Ramat Gan, Israel). In your
presentation, you don’t consider carotid plaque composition as
a risk factor. If you were given the information that a 60% stenos-
ing internal carotid artery plaque in an asymptomatic patient has
a giant vulnerable component, namely a sizable necrotic core
with a thin ﬁbrous cap, would you consider this rupture-prone pla-
que as risk-full, thus necessitating carotid endarterectomy?
Dr Wallaert. Yes, I probably would consider that a high-risk
patient and would certainly factor those details into my decision to
operate or not for that individual. Unfortunately, this study uses
registry data that do not include measures such as the plaque char-
acteristics you described. Therefore, we were unable to account for
such variables in our analysis.
Dr William Jordan (Birmingham, Ala). I actually have some
disagreement with your conclusions speciﬁcally relative to your
high-risk cohort. I think you’re looking at the glass as half empty
instead of half full. Speciﬁcally, while you’ve identiﬁed this high-
risk group after the operation, could their survival be improved if
we directed more efforts on treating their medical disease? Stated
differently, I don’t believe the operation itself is the incident thatcauses the decreased survival; potentially, they might still beneﬁt
from the carotid repair if we can improve their medical therapy.
Can you comment?
Dr Wallaert. I agree. I don’t believe that operation itself is
responsible for reduced long-term survival in these high-risk
patients. I do believe, however, that it is our responsibility as
surgeons to take into consideration patient characteristics that
may make an individual less likely to beneﬁt from an operation
because he or she has medical comorbidities that will reduce his
or her lifespan and thus their opportunity to beneﬁt from stroke
prevention provided by an endarterectomy.
We recognize that our deﬁnition of poor long-term survival
or “inappropriate” is somewhat arbitrary, and many would argue
that a 50% 5-year survival is perfectly reasonable. I think that
deﬁnition of appropriateness is going to vary based on the indi-
vidual patient and his or her surgeon. Ultimately, it’s going to
come down to you, your patient, and a discussion about that
individual’s risk of postoperative mortality or stroke, as well as
their long-term chance of surviving to beneﬁt from a durable
repair.
Dr Jordan. Can your group then improve on the medical
therapy afterwards? Potentially, if we did a better job of taking
care of heart disease or lung disease, then they might have better
long-term survival.
Dr Wallaert. That’s certainly a consideration and I agree that
optimizing medical management of patients’ comorbidities, preop-
eratively and postoperatively, is critical. Unfortunately, we don’t
have data to suggest whether we are doing a good job of this or
not, so I can’t comment on the effect improved medical manage-
ment on our result. I suspect it would have little impact.INVITED COMMENTARYCaron B. Rockman, MD, RVT, New York, NYThere has been recent renewed scrutiny into the appropriate-
ness of performing prophylactic interventions on patients with severe
asymptomatic carotid artery atherosclerotic plaque to prevent future
strokes. Prophylactic carotid endarterectomy (CEA) has been
demonstrated in several randomized, prospective trials to provide
superior stroke prevention compared with contemporaneous
medical therapies in patients with severe carotid artery stenosis.
However, ongoing current discussions have focused on the premise
that the incidence of ischemic stroke may be decreasing and the
hypothesis that improved pharmacologic therapies, such as statin
medications, may be responsible for the decreasing stroke rate.
If one were a proponent of these hypotheses, it would be natural
to conclude that the risk-beneﬁt balancewith regard to surgical treat-
ment of asymptomatic severe carotid artery atherosclerosis might
have indeed tipped toward the medical therapy side of the seesaw.
Nevertheless, stroke remains the fourth leading cause of death
in the United States and the leading cause of long-term disability
and institutionalization. Stroke represents a major worldwide
patient and economic burden. The treatment of stroke, once it
has occurred, is generally unsuccessful. Clearly, all physicians would
be eager for improved tools to designate those patients at highest
risk for stroke as well as for enriched stroke-prevention strategies
and methods. With regard to prophylactic carotid endarterectomy
(CEA) in asymptomatic patients, knowledge about the patient’s
long-term survival is critical to properly evaluate whether a patient
will derive potential beneﬁt from prophylactic surgical intervention.
In this regard, the current study from the Vascular Study
Group of New England provides important data for the clinician
who evaluates patients with carotid artery disease. A large cohort
of asymptomatic patients who underwent CEA was evaluated,
and the perioperative stroke and mortality rates were extremely
low. More than 80% of the patients who underwent CEA achieved
5-year survival after their surgery. On the basis of randomized,
prospective data, this should theoretically be long enough to attainstroke-prevention beneﬁt in appropriately selected asymptomatic
patients. A patient should probably not be considered for pro-
phylactic CEA if his or her individual life expectancy is felt to
be <3 years.
However, 5% of the patient cohort was deemed to be at “high
risk” for early death because of comorbid conditions; only 51% of
patients in this category would be expected to achieve 5-year
survival. In addition, 68% of patients who underwent CEA were
deemed “moderate risk,” and only 80% of the patients in this cate-
gory would be expected to achieve 5-year survival. Clearly, there is
room for improvement in patient selection in this regard.
The major risk factors for early mortality included advanced
age $80 years (hazard ratio, 3.94) and dialysis-dependent renal
failure (hazard ratio, 3.41); these are not unexpected ﬁndings.
Unfortunately, the current report is somewhat less successful in
discriminating the relative contribution of more “minor” risk
factors for death, including congestive heart failure, chronic
obstructive pulmonary disease, insulin-dependent diabetes, and
the degree of contralateral carotid artery stenosis. Most patients
who are evaluated for asymptomatic carotid artery disease will be
aged <80 years and not in dialysis-dependent failure; most will
also likely have at least one “minor” risk for early mortality, placing
them in the “moderate-risk” category according to the risk strati-
ﬁcation system derived by the authors.
Nevertheless, the current data do provide a valid framework
for clinicians to contemplate when choosing appropriate asymp-
tomatic patients for CEA. In addition to considering the degree
of stenosis, other anatomic and morphologic characteristics,
and the individual patient’s risk of perioperative complications after
surgery, it is critical for the surgeon to weigh the patient’s long-term
survival in order to achieve an appropriate stroke-prevention
beneﬁt. Certainly, patients deemed at “high risk” for early mortality
should probably not be considered for prophylactic CEA, and
patients at “moderate risk” need to be carefully considered.
